Pivotal study to PREVENT proliferative retinopathy funded by DFG
On Dec. 14, 2015, the DFG announced that Prof. Dr. Sascha Fauser, Dept. of Ophthalmology, University of Cologne and one of twelve principle investigators in the DFG research unit FOR 2240, is to receive additional clinical study funding. The study is concerned with proliferative vitreoretinopathy (PVR), which is the major cause for postoperative failure after surgery for rhegmatogenous retinal detachment. Fibrovascular scars lead to re-detachment and often to visual impairment. Prof. Fauser’s team has established a tool for estimating the risk of PVR. By selecting high-risk patients with this method, they plan to use 5-Fluorouracil and heparin intraoperatively as a prophylactic therapy in a randomized, double-blind trial. According to Prof. Fauser, this has the potential to be the first effective prophylactic standard treatment to prevent PVR.